Effects of drug combinations on smooth muscle cell proliferation

An isobolographic analysis

Tom J. Parry, Rathna Thyagarajan, Dennis Argentieri, Robert Falotico, John Siekierka, Ronald J. Tallarida

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Although sirolimus is a potent inhibitor of vascular smooth muscle cell (VSMC) proliferation and is effective at preventing restenosis in the majority of clinical revascularization procedures employing sirolimus-eluting stents, some VSMC may escape the antiproliferative effects of sirolimus. The present study examines the effects of combining sirolimus with other known cell cycle-specific antiproliferative agents (cladribine, topotecan or etoposide) on cultured coronary artery VSMC proliferation and utilizes a novel isobolographic approach to determine whether sirolimus/antiproliferative agent combinations produce subadditive, additive or supraadditive potentiation of antiproliferative activity. All agents were found to inhibit coronary artery VSMC proliferation in a dose-dependent manner. Cladribine was found to potentiate the antiproliferative activity of sirolimus in either an additive or supraadditive manner, depending upon the cladribine concentration. Topotecan potentiated the sirolimus antiproliferative activity by simple additivity while etoposide yielded subadditive potentiation. The present results demonstrate the utility of isobolographic analysis for identifying and optimizing antiproliferative drug combinations.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalEuropean Journal of Pharmacology
Volume532
Issue number1-2
DOIs
StatePublished - 17 Feb 2006

Fingerprint

Drug Combinations
Sirolimus
Smooth Muscle Myocytes
Cell Proliferation
Cladribine
Vascular Smooth Muscle
Topotecan
Etoposide
Coronary Vessels
Stents
Cell Cycle

Keywords

  • Drug combination
  • Isobolographic analysis
  • Sirolimus
  • Vascular smooth muscle

Cite this

Parry, Tom J. ; Thyagarajan, Rathna ; Argentieri, Dennis ; Falotico, Robert ; Siekierka, John ; Tallarida, Ronald J. / Effects of drug combinations on smooth muscle cell proliferation : An isobolographic analysis. In: European Journal of Pharmacology. 2006 ; Vol. 532, No. 1-2. pp. 38-43.
@article{daf33a8e73bb4c56a2813e10177c7adf,
title = "Effects of drug combinations on smooth muscle cell proliferation: An isobolographic analysis",
abstract = "Although sirolimus is a potent inhibitor of vascular smooth muscle cell (VSMC) proliferation and is effective at preventing restenosis in the majority of clinical revascularization procedures employing sirolimus-eluting stents, some VSMC may escape the antiproliferative effects of sirolimus. The present study examines the effects of combining sirolimus with other known cell cycle-specific antiproliferative agents (cladribine, topotecan or etoposide) on cultured coronary artery VSMC proliferation and utilizes a novel isobolographic approach to determine whether sirolimus/antiproliferative agent combinations produce subadditive, additive or supraadditive potentiation of antiproliferative activity. All agents were found to inhibit coronary artery VSMC proliferation in a dose-dependent manner. Cladribine was found to potentiate the antiproliferative activity of sirolimus in either an additive or supraadditive manner, depending upon the cladribine concentration. Topotecan potentiated the sirolimus antiproliferative activity by simple additivity while etoposide yielded subadditive potentiation. The present results demonstrate the utility of isobolographic analysis for identifying and optimizing antiproliferative drug combinations.",
keywords = "Drug combination, Isobolographic analysis, Sirolimus, Vascular smooth muscle",
author = "Parry, {Tom J.} and Rathna Thyagarajan and Dennis Argentieri and Robert Falotico and John Siekierka and Tallarida, {Ronald J.}",
year = "2006",
month = "2",
day = "17",
doi = "10.1016/j.ejphar.2005.12.042",
language = "English",
volume = "532",
pages = "38--43",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

Effects of drug combinations on smooth muscle cell proliferation : An isobolographic analysis. / Parry, Tom J.; Thyagarajan, Rathna; Argentieri, Dennis; Falotico, Robert; Siekierka, John; Tallarida, Ronald J.

In: European Journal of Pharmacology, Vol. 532, No. 1-2, 17.02.2006, p. 38-43.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effects of drug combinations on smooth muscle cell proliferation

T2 - An isobolographic analysis

AU - Parry, Tom J.

AU - Thyagarajan, Rathna

AU - Argentieri, Dennis

AU - Falotico, Robert

AU - Siekierka, John

AU - Tallarida, Ronald J.

PY - 2006/2/17

Y1 - 2006/2/17

N2 - Although sirolimus is a potent inhibitor of vascular smooth muscle cell (VSMC) proliferation and is effective at preventing restenosis in the majority of clinical revascularization procedures employing sirolimus-eluting stents, some VSMC may escape the antiproliferative effects of sirolimus. The present study examines the effects of combining sirolimus with other known cell cycle-specific antiproliferative agents (cladribine, topotecan or etoposide) on cultured coronary artery VSMC proliferation and utilizes a novel isobolographic approach to determine whether sirolimus/antiproliferative agent combinations produce subadditive, additive or supraadditive potentiation of antiproliferative activity. All agents were found to inhibit coronary artery VSMC proliferation in a dose-dependent manner. Cladribine was found to potentiate the antiproliferative activity of sirolimus in either an additive or supraadditive manner, depending upon the cladribine concentration. Topotecan potentiated the sirolimus antiproliferative activity by simple additivity while etoposide yielded subadditive potentiation. The present results demonstrate the utility of isobolographic analysis for identifying and optimizing antiproliferative drug combinations.

AB - Although sirolimus is a potent inhibitor of vascular smooth muscle cell (VSMC) proliferation and is effective at preventing restenosis in the majority of clinical revascularization procedures employing sirolimus-eluting stents, some VSMC may escape the antiproliferative effects of sirolimus. The present study examines the effects of combining sirolimus with other known cell cycle-specific antiproliferative agents (cladribine, topotecan or etoposide) on cultured coronary artery VSMC proliferation and utilizes a novel isobolographic approach to determine whether sirolimus/antiproliferative agent combinations produce subadditive, additive or supraadditive potentiation of antiproliferative activity. All agents were found to inhibit coronary artery VSMC proliferation in a dose-dependent manner. Cladribine was found to potentiate the antiproliferative activity of sirolimus in either an additive or supraadditive manner, depending upon the cladribine concentration. Topotecan potentiated the sirolimus antiproliferative activity by simple additivity while etoposide yielded subadditive potentiation. The present results demonstrate the utility of isobolographic analysis for identifying and optimizing antiproliferative drug combinations.

KW - Drug combination

KW - Isobolographic analysis

KW - Sirolimus

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=33644513715&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2005.12.042

DO - 10.1016/j.ejphar.2005.12.042

M3 - Article

VL - 532

SP - 38

EP - 43

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-2

ER -